Almeida, Antonio MPrebet, ThomasItzykson, RaphaelRamos, FernandoAl-Ali, HaifaShammo, JamilePinto, RicardoMaurillo, LucaWetzel, JaimeMusto, PellegrinoVan De Loosdrecht, Arjan ACosta, Maria JoaoEsteves, SusanaBurgstaller, SonjaStauder, ReinhardAutzinger, Eva MLang, AloisKrippl, PeterGeissler, DietmarFalantes, Jose FranciscoPedro, CarmenBargay, JoanDeben, GuillermoGarrido, AnaBonanad, SantiagoDiez-Campelo, MariaThepot, SylvainAdes, LionelSperr, Wolfgang RValent, PeterFenaux, PierreSekeres, Mikkael AGreil, RichardPleyer, Lisa2023-01-252023-01-252017-04-14http://hdl.handle.net/10668/11108Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/acute erythroleukemiaazacitidinedecitabineAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAzacitidineBiomarkersBone MarrowCytogenetic AnalysisDecitabineFemaleHumansLeukemia, Erythroblastic, AcuteMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesSurvival AnalysisTreatment Outcomeresearch article28420120open access10.3390/ijms180408371422-0067PMC5412421https://www.mdpi.com/1422-0067/18/4/837/pdf?version=1492178743https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412421/pdf